PTCT - PTC THERAPEUTICS, INC.
IEX Last Trade
45.395
9.975 21.974%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:51 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$35.42
9.98
28.16%
Fundamental analysis
18%
Profitability
18%
Dept financing
25%
Liquidity
32%
Performance
14%
Performance
5 Days
-1.92%
1 Month
5.49%
3 Months
23.77%
6 Months
29.02%
1 Year
64.25%
2 Year
24.35%
Key data
Stock price
$45.40
DAY RANGE
$35.42 - $46.04
52 WEEK RANGE
$25.10 - $54.16
52 WEEK CHANGE
$54.41
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Stuart W. Peltz
Region: US
Website: ptcbio.com
Employees: 1,410
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ptcbio.com
Employees: 1,410
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
PTC Therapeutics focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; Tegsedi and Waylivra for the. treatment of rare diseases in Latin America and the Caribbean. PTC518 is being developed for Huntington's disease.
Recent news